Find out all news and events of Vaccine Research Institute or in link with the VIH.

April 13, 2019

Press release: Immune responses in Ebola survivors 2 years after infection provide clues for vaccine development

Scientists have discovered that 2 years after infection, West African Ebola survivors exhibit memory immune responses—including specific T cells against Ebola virus. They believe their discovery opens up the possibility of improving Ebola vaccines by boosting key immune cells needed for long-lasting protective immunity.

The new research is being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands (13–16 April).

“Ebola survivors’ immune responses could help to determine which kind of immune responses have to be induced by a vaccine to efficiently fight the virus”, says Dr Aurelie Wiedemann from the Vaccine Research Institute, Creteil, France who led the research. “Our findings indicate which specific immune responses are persisting in survivors a long time after infection” T cells are a key component of antiviral immune responses in addition to the antibody-producing cells, but little is known about T cell responses to Ebola virus disease.

This is the first time that Ebola disease-specific responses in T cells have been demonstrated in human survivors 2 years after infection, researchers say.

The 2013–2016 outbreak of Ebola virus disease in West Africa was the largest Ebola outbreak in history—with an estimated 28,616 cases identified, resulting in 11,310 deaths in Guinea, Sierra Leone, and Liberia. More than 10,000 people infected with Ebola virus survived.

Previous research indicates that robust immune responses are associated with a better prognosis in individuals with Ebola virus disease. However, prevention efforts have been limited by the lack of knowledge about how to generate a protective immune response against this virulent pathogen. Correlates of protection that should be induced by an efficient vaccine are still not known in Ebola Virus disease.

To provide more evidence, Wiedemann and colleagues examined how the immune system responded to Ebola virus disease 2 years after infection in 35 adult survivors (median age 30 years) from the PostEboGui study—an observational cohort of 802 survivors of the 2013–2016 Ebola outbreak recruited in Guinea who have been declared clear of the virus.

The researchers analysed blood samples to characterise the T-cell (helper) and cytotoxic T-cells (that destroy infected cells that produce the virus) response to Ebola virus glycoprotein in these survivors. They also used gene expression profiling to compare the blood of Ebola virus disease survivors and a control group of 39 Guineans (median age 25 years) without a history of Ebola virus disease.

Compared to control individuals, all survivors exhibited Ebola specific immunoglobulin-G (IgG) antibodies testifying to their past Ebola disease.  Analysis of blood markers showed that survivors have persistent inflammation more than 2 years after healing. This status may also explain some long-term clinical symptoms (eg, headache, fatigue, muscle pain, joint pain) described in these subjects.

In-vitro stimulation of mononuclear cells from survivors with Ebola antigens revealed the presence of memory T cells capable of producing cytokines (molecules produced by cells of the immune system in response to a pathogen), suggesting that these cells might be able to control and/or clear Ebola virus.

Further analysis showed that the gene expression profile of these survivors differed from healthy individuals. The authors speculate that further in-depth analysis of these genes could provide clues to factors associated with better clinical outcomes in Ebola-infected individuals.    

“Our study of Ebola virus disease survivors could provide critical data to develop strategies for mimicking the resilience which some individuals have demonstrated after being infected, and help to better identify a correlate of protection against Ebola virus disease”, says Dr Wiedemann.


Dr Aurelie Wiedemann, Vaccine Research Institute, Creteil, France T) +33 149813735 E)

Alternative Contact in the ECCMID Press Room: Tony Kirby T) + 44 (0)7834 385827 E)


Notes to editors: The authors declare no conflicts of interest.

This press release is based on mini-oral e-poster presentation 1225 at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The material has been peer reviewed by the congress selection committee. There is no full paper at this stage, but the authors are happy to answer your questions. The study has not yet been submitted to a journal for publication.

For full abstract, click here

For full poster, click here